Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 8:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Exenatide twice daily (BID) Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women

NCT00456885
View directory record Official record
Conditions
Obesity, Impaired Glucose Tolerance
Interventions
exenatide, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Exenatide in Patients With Diabetic Neuropathy

NCT00855439
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetic Peripheral Neuropathy
Interventions
Exenatide, Glargine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 4 Interventional Results available

Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM

NCT02981069
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dapagliflozin, Exenatide, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 3 Interventional

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

NCT00039013
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
AC2993, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
129
States / cities
Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Not applicable Interventional Results available

Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine

NCT01089569
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide, Insulin Glargine
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2017 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 4 Interventional Results available

Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes

NCT01432405
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide, Pioglitazone
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin

NCT00603239
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
Birmingham, Alabama • Concord, California • Fresno, California + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 3 Interventional Results available

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

NCT00518882
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
liraglutide, exenatide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 80 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
61
States / cities
Birmingham, Alabama • Goodyear, Arizona • Artesia, California + 54 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 2 Interventional Results available

Exenatide in Extreme Pediatric Obesity

NCT01237197
View directory record Official record
Conditions
Obesity
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 19 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 4 Interventional

A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus

NCT00477581
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, sitagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
19
States / cities
Los Angeles, California • Spring Valley, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Exenatide as Monotherapy

NCT00381342
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Idaho Falls, Idaho • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes

NCT00353834
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide, Glargine Insulin
Drug
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Sep 30, 2026, 8:34 AM EDT
Not listed Phase 2Phase 3 Interventional

The Effects of Exenatide After Gastric Restriction

NCT00872378
View directory record Official record
Conditions
Morbid Obesity
Interventions
Exenatide, Placebo
Drug
Lead sponsor
Advanced Specialty Care
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Bend, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 31, 2009 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 2 Interventional

Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes

NCT00064714
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
AC2993 (exenatide), daclizumab (immunosuppressive)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Weight Loss With Exenatide Treatment

NCT01590433
View directory record Official record
Conditions
Obesity
Interventions
Exenatide, Placebo, Dietary counseling
Drug · Behavioral
Lead sponsor
Jody Dushay
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 4 Interventional Results available

Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults

NCT00845507
View directory record Official record
Conditions
Weight Gain
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Sep 30, 2026, 8:34 AM EDT
Terminated Phase 4 Interventional Results available

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

NCT02072096
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Glimepiride, Metformin, Pioglitazone, Acarbose, Linagliptin, Sitagliptin, Liraglutide, Insulin Glargine, Exenatide once weekly (QW), Exenatide twice daily (BID)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
65 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
Miami, Florida • New Port Richey, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Sep 30, 2026, 8:34 AM EDT
Terminated Phase 4 Interventional Results available

Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart Failure

NCT00799435
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Heart Failure, Diastolic
Interventions
Exenatide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of Exenatide on Hypothalamic Obesity

NCT01061775
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Exenatide
Drug
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
10 Years to 21 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Orange, California • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 4 Interventional Results available

Effect of Exenatide on Liver and Heart Fat and Inflammation

NCT01951651
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Exenatide, Glipizide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Not applicable Interventional Results available

Impact of Exenatide on Sleep in Type 2 Diabetes

NCT01136798
View directory record Official record
Conditions
Type 2 Diabetes, Sleep Disordered Breathing
Interventions
Exenatide, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 3 Interventional

An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

NCT01876849
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Renton, Washington
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 2 Interventional

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

NCT00241423
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Washington D.C., District of Columbia • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Sep 30, 2026, 8:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying

NCT02160990
View directory record Official record
Conditions
Obesity
Interventions
Exenatide, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 30, 2026, 8:34 AM EDT